Biora Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOR research report →
Companywww.bioratherapeutics.com
Biora Therapeutics, Inc. , a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake.
- CEO
- Aditya Mohanty
- IPO
- 2020
- Employees
- 58
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $994.99K
- P/E
- -0.00
- P/S
- 0.34
- P/B
- -0.00
- EV/EBITDA
- -0.28
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1678575.00%
- Net Margin
- -3102875.00%
- ROE
- 121.86%
- ROIC
- 232.28%
Growth & Income
- Revenue
- $4.00K · -98.69%
- Net Income
- $-124,115,000 · -225.27%
- EPS
- $-78.70 · -1129.69%
- Op Income
- $-67,143,000
- FCF YoY
- 25.47%
Performance & Tape
- 52W High
- $0.38
- 52W Low
- $0.15
- 50D MA
- $0.22
- 200D MA
- $0.22
- Beta
- 1.28
- Avg Volume
- 60.81K
Get TickerSpark's AI analysis on BIOR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BIOR Coverage
We haven't published any research on BIOR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BIOR Report →